ATHA Key Statistics, Chart & Performance
The current stock price of ATHA is 4.35 USD. In the past month the price increased by 4.32%. In the past year, price decreased by -33.61%.
ATHA Latest News, Press Relases and Analysis
ATHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.16B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.10B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About ATHA
Company Profile
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. The company has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.
Company Info
ATHIRA PHARMA INC
18706 North Creek Parkway, Suite 104, Box 352141
Bothell WASHINGTON 98011 US
CEO: Leen Kawas
Employees: 26
Phone: 14256208501
ATHIRA PHARMA INC / ATHA FAQ
What does ATHA do?
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. The company has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.
What is the current price of ATHA stock?
The current stock price of ATHA is 4.35 USD. The price decreased by -3.76% in the last trading session.
What is the dividend status of ATHIRA PHARMA INC?
ATHA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATHA stock?
ATHA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in ATHIRA PHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ATHA.
What is the employee count for ATHA stock?
ATHIRA PHARMA INC (ATHA) currently has 26 employees.
What is ATHIRA PHARMA INC worth?
ATHIRA PHARMA INC (ATHA) has a market capitalization of 17.14M USD. This makes ATHA a Nano Cap stock.
ATHA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ATHA. When comparing the yearly performance of all stocks, ATHA is a bad performer in the overall market: 76.44% of all stocks are doing better.
ATHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATHA. The financial health of ATHA is average, but there are quite some concerns on its profitability.
ATHA Financial Highlights
Over the last trailing twelve months ATHA reported a non-GAAP Earnings per Share(EPS) of -6.17. The EPS decreased by -116.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.61% | ||
| ROE | -140.83% | ||
| Debt/Equity | 0 |